ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2519 • 2012 ACR/ARHP Annual Meeting

    IL-1β and TNF-α Regulate the Global and Locus-Specific hydroxymethylation  of Genomic DNA by Modulating the Expression and Activity of Tet-1 in Human OA Chondrocytes

    Abdul Haseeb1 and Tariq M. Haqqi2, 1Medicine/Rheumatology, Case Western Reserve University, Cleveland, OH, 2Medicine/Rheumatology/Haman 586, Metro Health Medical Center, Cleveland, OH

    Background/Purpose: 5-hydroxymethylcytosine (5-hmC), which is formed by the oxidation of 5-methylcytosine (5-mC), is a recently discovered epigenetic mark and is highest in brain and in…
  • Abstract Number: 2520 • 2012 ACR/ARHP Annual Meeting

    Suppressor of Cytokine Signaling 3 Is Reduced in Obese Patients with Osteoarthritis and Regulates Leptin Responses in Chondrocytes

    Anna Koskinen1, Katriina Vuolteenaho1, Riku Korhonen1, Teemu Moilanen2 and Eeva Moilanen1, 1The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, 2Coxa Hospital for Joint Replacement, Tampere, Finland

    Background/Purpose: Leptin is an adipokine whose concentrations in circulation are proportional to body fat stores and body mass index (BMI). Initially leptin was discovered to…
  • Abstract Number: 2521 • 2012 ACR/ARHP Annual Meeting

    Immunoglobulin G Fc Receptor Activity in Vivo Is Under Complement Control

    Eveline Y. Wu1, Haixiang Jiang2, C. Garren Hester3 and Michael M. Frank2, 1DUMC Box 3212, Duke Univ Med Ctr, Durham, NC, 2Pediatrics, Duke Univ Med Ctr, Durham, NC, 3Duke Univ Med Ctr, Durham, NC

    Background/Purpose: Immunoglobulin G receptors (FcγR) are critical in the development of autoimmunity and pathogenesis of immune complex (IC) diseases. Although ICs activate complement, contributing to…
  • Abstract Number: 2522 • 2012 ACR/ARHP Annual Meeting

    M-Ficolin, an Activator of the Complement System, Is the Strongest Predictor of Both DAS28 Remission and Low Disease Activity in a Cohort of 180 Early DMARD Naïve Rheumatoid Arthritis Patients Followed in the Opera-Study

    Christian G. Ammitzbøll1, Jens Christian Jensenius2, Torkell Ellingsen3, Steffen Thiel2, Kim Hørslev-Petersen4, Merete L. Hetland5, Peter Junker6, Julia Johansen7, Mikkel Østergaard8, Jan Pødenphant9 and Kristian Stengaard-Pedersen1, 1Arhus University Hospital, Aarhus, Denmark, 2Biomedicine, Aarhus University, Aarhus, Denmark, 3Silkeborg Regional Hospital, Silkeborg, Denmark, 4Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, 5Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 6Odense University Hospital, Odense, Denmark, 7Glostrup Hospital, Glostrup, Denmark, 8Copenhagen University Hospital Glostrup, Glostrup, Denmark, 9Gentofte Hospital

    Background/Purpose: M-ficolin is a soluble pattern recognition molecule that activates the complement system. We recently reported a factor 300 difference in the synovial fluid M-ficolin…
  • Abstract Number: 2523 • 2012 ACR/ARHP Annual Meeting

    Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a Toll-Like Receptor 2 and Interleukin-1 Driven Th17 Response

    Shahla Abdollahi-Roodsaz1, Sabrina Garcia de Aquino2, Marije I. Koenders3, Fons A. van de Loo4, Ger J. Pruijn5, Mario J. Avila Campos6, Fernando Q. Cunha7, Joni A. Cirelli2 and Wim B. van den Berg1, 1Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Diagnosis and Oral Surgery, Periodontic Division, Araraquara Dental School, Sao Paolo, Brazil, 3Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 4Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Department of Biomolecular Chemistry, Radboud University, Nijmegen, Netherlands, 6Department of Microbiology, Institute of Biomedical Sciences—ICB/USP, Sao Paulo, Brazil, 7Department of Pharmacology, School of Medicine of Ribeirao Preto, Sao Paolo, Brazil

    Background/Purpose: The periodontal pathogen Porphyromonas gingivalishas been associated with the pathogenesis of rheumatoid arthritis (RA) because of its ability to citrullinate mammalian proteins and to…
  • Abstract Number: 2524 • 2012 ACR/ARHP Annual Meeting

    Snapin Is Critical for the Maturation of Autophagosome and Phagosome in Macrophages

    Bo Shi1, Qiquan Huang2, Robert Birkett1, Renee E. Koessler3, Andrea Dorfleutner4, Christian Stehlik4 and Richard M. Pope5, 1Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, 4Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose:  We found that Snapin, a SNARE complex protein required for synaptic vesicle docking and fusion, was significantly increased in rheumatoid arthritis (RA) synovial tissue…
  • Abstract Number: 2525 • 2012 ACR/ARHP Annual Meeting

    Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants

    Linda M. Hartkamp1, Inge E. van Es1, Jay S. Fine2, Michael Smith2, John Woods2, Satwant Narula3, Julie DeMartino2, Paul P. Tak4 and Kris A. Reedquist1, 1Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, 3Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ, 4Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic and progressive autoinflammatory disorder characterized by the infiltration of inflammatory cells, including B-cells, T-cells and macrophages, in the…
  • Abstract Number: 2486 • 2012 ACR/ARHP Annual Meeting

    Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis

    Eun Bong Lee1, Roy Fleischmann2, Stephen Hall3, Ronald F. van Vollenhoven4, John Bradley5, David Gruben6, Tamas Koncz7, Sriram Krishnaswami5, Gene Wallenstein6, Samuel H. Zwillich5, Bethanie E. Wilkinson6 and the ORAL Start Investigators8, 1Seoul National University, Seoul, South Korea, 2Metroplex Clinical Research Center, Dallas, TX, 3Cabrini Medical Centre, Melbourne, Australia, 4Karolinska Institute, Stockholm, Sweden, 5Pfizer Inc, Groton, CT, 6Pfizer Inc., Groton, CT, 7Pfizer Inc., New York, NY, 8Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This Phase 3, 24-mo study (ORAL…
  • Abstract Number: 2487 • 2012 ACR/ARHP Annual Meeting

    24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

    Mark C. Genovese1, Edward Keystone2, Peter Taylor3, Edit Drescher4, Pierre-Yves Berclaz5, Chin H. Lee5, Douglas E. Schlichting5, Scott D. Beattie5, Rosanne K. Fidelus-Gort6, Monica E. Luchi6 and William Macias5, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2University of Toronto, Toronto, ON, Canada, 3NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 4Internal Medicine and Rheumatology, Veszprém Csolnoky Ferenc County Hospital, Department of Rheumatology and Physical Rehabilitation, Veszprém, Hungary, 5Eli Lilly and Company, Indianapolis, IN, 6E361/309, Incyte Corporation, Wilmington, DE

    Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 24 week blinded…
  • Abstract Number: 2488 • 2012 ACR/ARHP Annual Meeting

    Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

    Charles G. Peterfy1, Paul Emery2, Mark C. Genovese3, Edward Keystone4, Peter Taylor5, Pierre-Yves Berclaz6, Julie C. DiCarlo1, Chin H. Lee6, Douglas E. Schlichting6, Scott D. Beattie6, Monica E. Luchi7 and William Macias6, 1Spire Sciences LLC, Kentfield, CA, 2Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 3Division of Rheumatology, Stanford University, Palo Alto, CA, 4University of Toronto, Toronto, ON, Canada, 5NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 6Eli Lilly and Company, Indianapolis, IN, 7E361/309, Incyte Corporation, Wilmington, DE

    Background/Purpose: Baricitinib (formerly, LY3009104/ INCB028050 ) is a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT pathway. Primary results of this phase 2b…
  • Abstract Number: 2489 • 2012 ACR/ARHP Annual Meeting

    Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634

    Frédéric Vanhoutte1, Minodora Mazur2, Annegret Van der Aa1, Piet Wigerinck1 and Gerben van 't Klooster1, 1Galapagos NV, Mechelen, Belgium, 2Rheumatology, State Medical and Pharmaceutical University "Nicolae Testemitanu", Chisinau, Moldova

    Background/Purpose: Janus kinases (JAKs) are critical components in signaling pathways for a number of cytokines and growth factors, including those involved in the disease process…
  • Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting

    Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis

    K. L. Winthrop1, H. Valdez2, E. Mortensen3, R. Chew4, S. Krishnaswami5, T. Kawabata5 and R. Riese4, 1Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, 2Pfizer Inc., New York, NY, 3Global Medical Affairs, Pfizer Inc., Collegeville, PA, 4Pfizer Inc., Groton, CT, 5Pfizer Inc, Groton, CT

    Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
  • Abstract Number: 2491 • 2012 ACR/ARHP Annual Meeting

    IL-17 Expression Is Low in Psoriatic Arthritis Synovium Compared to Expression in Matched Skin Lesions

    Jennifer Belasco1, Hiroshi Mitsui1, Mayte Suarez-Farinas1, James S. Louie2, Nathan Wei3, Nicholas Gulati1 and James G. Krueger1, 1Krueger Laboratory, The Rockefeller University, New York, NY, 2Rheumatology, UCLA School of Medicine, Los Angeles, CA, 3Arthritis Treatment Center, Frederick, MD

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. It is known that treatment modalities are not equally effective for both skin…
  • Abstract Number: 2492 • 2012 ACR/ARHP Annual Meeting

    Protective and Pathogenic Effects of the IL-23 Family of Cytokines in Spondyloarthropathy in SKG Mice

    Helen Benham1, Linda Rehaume1, Merja Ruutu1, Jared Velasco1, Kristine Kikly2, Geoffrey Strutton3, Michael McGuckin4 and Ranjeny Thomas1, 1Diamantina Institute, Diamantina Institute University of Queensland, Brisbane, Australia, 2Biotechnology Discovery Research, Eli Lilly and Co., Indianapolis, 3Dept of Pathology, Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia, 4Mater Medical Research Institute, Brisbane, Australia

    Background/Purpose: , IL-23 is required for the expansion and maintenance of T cells and innate cells secreting IL-17 and IL-22. These cytokines are important for…
  • Abstract Number: 2493 • 2012 ACR/ARHP Annual Meeting

    The Presence of HLA-B27 Shapes Gut Microbiome Composition in Rats

    Mary H. Bach1, Russell N. Van Gelder2, Joel D. Taurog3 and James T. Rosenbaum4, 1Rheumatology, University of Washington Medical Center, Seattle, WA, 2Ophthalmology, University of Washington Medical Center, Seattle, WA, 3Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, 4Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR

    Background/Purpose: The association of spondyloarthropathies (SpA) with HLA-B27 was first described in 1973. However, the mechanism remains unknown. The HLA-B27-human beta2 microglobulin (B27/hβ2m) transgenic (TG)…
  • « Previous Page
  • 1
  • …
  • 2435
  • 2436
  • 2437
  • 2438
  • 2439
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology